List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5996212/publications.pdf Version: 2024-02-01

	57752	51602
7,844	44	86
citations	h-index	g-index
131	131	10555
docs citations	times ranked	citing authors
	citations 131	7,844 44 citations h-index 131 131

#	Article	IF	CITATIONS
1	High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: results from the IMPRES study. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 352-360.	4.0	11
2	Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease. American Heart Journal, 2022, 243, 127-139.	2.7	8
3	Association of periodic fasting lifestyles with survival and incident major adverse cardiovascular events in patients undergoing cardiac catheterization. European Journal of Preventive Cardiology, 2022, 28, 1774-1781.	1.8	17
4	Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial. American Heart Journal, 2022, 244, 125-134.	2.7	16
5	Intermittent fasting and changes in Galectin-3: A secondary analysis of a randomized controlled trial of disease-free subjects. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1538-1548.	2.6	8
6	A Small but Significantly Greater Incidence of Inflammatory Heart Disease Identified After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases, 2022, 9, ofab663.	0.9	4
7	Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort. BMJ Open, 2022, 12, e053864.	1.9	1
8	Association of periodic fasting with lower severity of COVID-19 outcomes in the SARS-CoV-2 prevaccine era: an observational cohort from the INSPIRE registry. BMJ Nutrition, Prevention and Health, 2022, 5, 145-153.	3.7	8
9	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovascular Research, 2021, 117, 1070-1077.	3.8	45
10	Vitamin D supplementation protects against reductions in plasma 25â€hydroxyvitamin D induced by openâ€heart surgery: Assessâ€d trial. Physiological Reports, 2021, 9, e14747.	1.7	6
11	Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. American Journal of Cardiology, 2021, 153, 58-64.	1.6	5
12	Absent or Mild Coronary Calcium Predicts Low-Risk Stress Test Results and Outcomes in Patients Considered for Flecainide Therapy. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 648-655.	2.0	0
13	Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial. European Heart Journal Open, 2021, 1, .	2.3	17
14	Preferential Metabolic Improvement by Intermittent Fasting in People with Elevated Baseline Red Cell Distribution Width: A Secondary Analysis of the WONDERFUL Randomized Controlled Trial. Nutrients, 2021, 13, 4407.	4.1	3
15	Free thyroxine within the normal reference range predicts risk of atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2020, 31, 18-29.	1.7	12
16	Long-term outcomes after low power, slower movement versus high power, faster movement irrigated-tip catheter ablation for atrial fibrillation. Heart Rhythm, 2020, 17, 184-189.	0.7	49
17	Stroke and dementia risk in patients with and without atrial fibrillation and carotid arterial disease. Heart Rhythm, 2020, 17, 20-26.	0.7	21
18	Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction. American Heart Journal, 2020, 221, 125-135.	2.7	22

#	Article	IF	CITATIONS
19	Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. European Heart Journal, 2020, 41, 3925-3932.	2.2	257
20	Smartphone 12-lead ECG—Exciting but must be handled with care. American Heart Journal, 2020, 226, 269.	2.7	2
21	Intermountain chronic disease risk score (ICHRON) validation for prediction of incident chronic disease diagnoses in an australian primary prevention population. European Journal of Internal Medicine, 2020, 79, 81-87.	2.2	2
22	Abstract 14607: Randomized Controlled Trial of Once-Per-Week Intermittent Fasting for the Reduction of Low-Density Lipoprotein Cholesterol. Circulation, 2020, 142, .	1.6	0
23	Abstract 16802: Economics and Outcomes of Sotalol and Dofetilide In-Patient Dosing Approaches in Patients With Atrial Fibrillation. Circulation, 2020, 142, .	1.6	0
24	Abstract 13889: The Influence of Depression on Dementia Risk in Patients With Atrial Fibrillation. Circulation, 2020, 142, .	1.6	0
25	Abstract 15389: Effect of Icosapent Ethyl on Changes in Coronary Plaque Characteristics at 9 Months in Patients With Elevated Triglycerides on Statin Therapy: Insights From EVAPORATE. Circulation, 2020, 142, .	1.6	4
26	Atrial Fibrillation and Dementia: Exploring the Association, Defining Risks and Improving Outcomes. Arrhythmia and Electrophysiology Review, 2019, 8, 8-12.	2.4	23
27	Pilot Study of Novel Intermittent Fasting Effects on Metabolomic and Trimethylamine N-oxide Changes During 24-hour Water-Only Fasting in the FEELGOOD Trial. Nutrients, 2019, 11, 246.	4.1	35
28	Augmented intelligence decision tool for stroke prediction combines factors from CHA ₂ DS ₂ â€VASc and the intermountain risk score for patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2019, 30, 1452-1461.	1.7	5
29	Mechanisms of Improved Mortality Following Ablation. Cardiology Clinics, 2019, 37, 177-183.	2.2	2
30	Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies. Cardiology and Therapy, 2019, 8, 91-102.	2.6	1
31	Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study. Clinical Cardiology, 2019, 42, 506-512.	1.8	18
32	CHA2DS2-VASc scores and Intermountain Mortality Risk Scores for the joint risk stratification of dementia among patients with atrial fibrillation. Heart Rhythm, 2019, 16, 3-9.	0.7	23
33	Prediction of Long-Term Incidence of Chronic Cardiovascular and Cardiopulmonary Diseases in Primary Care Patients for Population Health Monitoring: The Intermountain Chronic Disease Model (ICHRON). Mayo Clinic Proceedings, 2019, 94, 1221-1230.	3.0	7
34	Incomplete endothelialization of WatchmanTM Device: Predictors and Implications from Two Cases. Journal of Atrial Fibrillation, 2019, 11, 2164.	0.5	1
35	Practical laboratory-based clinical decision tools and associations with short-term bleeding and mortality outcomes. Clinica Chimica Acta, 2018, 482, 166-171.	1.1	0
36	Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease—Real-world experience within a large integrated health care system: The IMPRES study. Journal of Clinical Lipidology, 2018, 12, 1008-1018.e1.	1.5	8

#	Article	IF	CITATIONS
37	Vagus nerve injury symptoms after catheter ablation for atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 389-395.	1.2	9
38	Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Clinical Cardiology, 2018, 41, 13-19.	1.8	63
39	Atrial Fibrillation Ablation and its Impact on Stroke. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 2.	0.9	5
40	GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study. American Heart Journal, 2018, 202, 27-32.	2.7	26
41	Fiveâ€year impact of catheter ablation for atrial fibrillation in patients with a prior history of stroke. Journal of Cardiovascular Electrophysiology, 2018, 29, 221-226.	1.7	12
42	Improving CHA ₂ DS ₂ -VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation. Open Heart, 2018, 5, e000907.	2.3	16
43	Depression: are patient's receiving adequate treatment?. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 235-236.	4.0	0
44	The Impact of Gender on Atrial Fibrillation Incidence and Progression to Dementia. American Journal of Cardiology, 2018, 122, 1489-1495.	1.6	10
45	Extreme erythrocyte macrocytic and microcytic percentages are highly predictive of morbidity and mortality. JCI Insight, 2018, 3, .	5.0	10
46	The association of antidepressant and statin use with death and incident cardiovascular disease varies by depression severity. Psychology, Health and Medicine, 2017, 22, 919-931.	2.4	6
47	Atrial fibrillation incrementally increases dementia risk across all CHADS 2 and CHA 2 DS 2 VASc strata in patients receiving long-term warfarin. American Heart Journal, 2017, 188, 93-98.	2.7	41
48	The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 75-82.	1.6	4
49	Clinically Feasible Stratification of 3-Year Chronic Disease Risk in Primary Care: The Mental Health Integration Risk Score. Psychosomatics, 2017, 58, 395-405.	2.5	2
50	My APPROACH to the depressed patient after a myocardial infarction. Trends in Cardiovascular Medicine, 2017, 27, 225.	4.9	1
51	The association of depression at any time to the risk of death following coronary artery disease diagnosis. European Heart Journal Quality of Care & Clinical Outcomes, 2017, 3, 296-302.	4.0	56
52	Longâ€ŧerm aspirin does not lower risk of stroke and increases bleeding risk in lowâ€risk atrial fibrillation ablation patients. Journal of Cardiovascular Electrophysiology, 2017, 28, 1241-1246.	1.7	2
53	Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. American Journal of Cardiology, 2016, 118, 210-214.	1.6	123
54	Long-term influence of body mass index on cardiovascular events after atrial fibrillation ablation. Journal of Interventional Cardiac Electrophysiology, 2016, 46, 259-265.	1.3	24

#	Article	IF	CITATIONS
55	Improvement in the predictive ability of the Intermountain Mortality Risk Score by adding routinely collected laboratory tests such as albumin, bilirubin, and white cell differential count. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1619-1628.	2.3	7
56	Utility of high density lipoprotein particle concentration in predicting future major adverse cardiovascular events among patients undergoing angiography. Clinical Biochemistry, 2016, 49, 1122-1126.	1.9	8
57	Atrial Fibrillation Patients Treated With Longâ€Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Longâ€Term Warfarin for Other Indications. Journal of the American Heart Association, 2016, 5, .	3.7	43
58	A Comparison of Remote Magnetic Irrigated Tip Ablation versus Manual Catheter Irrigated Tip Catheter Ablation With and Without Force Sensing Feedback. Journal of Cardiovascular Electrophysiology, 2016, 27, S5-S10.	1.7	32
59	Atrial fibrillation: a risk factor or risk marker?. European Heart Journal, 2016, 37, 2890-2892.	2.2	18
60	The Impact of Age on 5‥ear Outcomes After Atrial Fibrillation Catheter Ablation. Journal of Cardiovascular Electrophysiology, 2016, 27, 141-146.	1.7	68
61	Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. American Journal of Cardiology, 2016, 117, 794-799.	1.6	113
62	The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study. European Journal of Preventive Cardiology, 2016, 23, 769-776.	1.8	4
63	Incidence of Dementia in Relation to Genetic Variants at PITX2, ZFHX3, and ApoE Îμ4 in Atrial Fibrillation Patients. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 171-177.	1.2	30
64	Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Longâ€Term Risk of Dementia. Journal of Cardiovascular Electrophysiology, 2015, 26, 1180-1186.	1.7	40
65	The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm, 2015, 12, 681-686.	0.7	72
66	Five‥ear Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction. Journal of Cardiovascular Electrophysiology, 2015, 26, 363-370.	1.7	63
67	Pulmonary-Specific Intermountain Risk Score Predicts All-Cause Mortality via Spirometry, the Red Cell Distribution Width, and Other Laboratory Parameters. Respiratory Care, 2015, 60, 1314-1323.	1.6	10
68	Association of the dispersion in red blood cell volume with mortality. European Journal of Clinical Investigation, 2015, 45, 541-549.	3.4	16
69	Long-Term Natural History of Adult Wolff–Parkinson–White Syndrome Patients Treated With and Without Catheter Ablation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1465-1471.	4.8	44
70	HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative. European Heart Journal, 2015, 36, 22-30.	2.2	142
71	Coronary Artery Plaque Volume and Obesity in Patients with Diabetes: The Factor-64 Study. Radiology, 2014, 272, 690-699.	7.3	35
72	Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High-Risk Patients With Diabetes. JAMA - Journal of the American Medical Association, 2014, 312, 2234.	7.4	317

#	Article	IF	CITATIONS
73	Clinical Predictors of Risk for Atrial Fibrillation. Mayo Clinic Proceedings, 2014, 89, 1498-1505.	3.0	46
74	Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm, 2014, 11, 2206-2213.	0.7	130
75	Patients treated with catheter ablation for ventricular tachycardia after an ICD shock have lower long-term rates of death and heart failure hospitalization than do patients treated with medical management only. Heart Rhythm, 2014, 11, 533-540.	0.7	38
76	A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL3+IDL]). Lipids in Health and Disease, 2013, 12, 55.	3.0	11
77	Validation and Quantification of Genetic Determinants of Lipoprotein-a Levels and Predictive Value for Angiographic Coronary Artery Disease. American Journal of Cardiology, 2013, 112, 799-804.	1.6	14
78	Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm, 2013, 10, 1272-1277.	0.7	130
79	Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm, 2013, 10, 1257-1262.	0.7	66
80	Intracardiac Ultrasound for Esophageal Anatomic Assessment and Localization During Left Atrial Ablation for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2013, 24, 33-39.	1.7	22
81	Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thrombosis and Haemostasis, 2013, 109, 744-754.	3.4	27
82	Repeated Measurement of the Intermountain Risk Score Enhances Prognostication for Mortality. PLoS ONE, 2013, 8, e69160.	2.5	15
83	Panoptic total cardiovascular risk prediction using all predictors versus optimized risk assessment using variable subsets. Future Cardiology, 2012, 8, 765-778.	1.2	4
84	Efficacy and safety of ventricular tachycardia ablation with mechanical circulatory support compared with substrate-based ablation techniques. Europace, 2012, 14, 709-714.	1.7	59
85	Pulmonary-Specific Intermountain Risk Score: Derivation and Validation of Risk Scores for Mortality Among Patients Undergoing Pulmonary Function Testing. Chest, 2012, 142, 785A.	0.8	7
86	Circulating 25-Hydroxy-Vitamin D and Risk of Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 819-829.	2.2	524
87	Relation of Routine, Periodic Fasting to Risk of Diabetes Mellitus, and Coronary Artery Disease in Patients Undergoing Coronary Angiography. American Journal of Cardiology, 2012, 109, 1558-1562.	1.6	52
88	Trends in early and late mortality in patients undergoing coronary catheterization for myocardial infarction: implications on observation periods and risk factors to determine ICD candidacy. Heart Rhythm, 2011, 8, 1460-1466.	0.7	11
89	Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: Dependent or independent risk factors?. American Heart Journal, 2011, 162, 331-339.e2.	2.7	127
90	Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population. Clinica Chimica Acta, 2011, 412, 2094-2099.	1.1	168

#	Article	IF	CITATIONS
91	The intermountain risk score predicts incremental age-specific long-term survival and life expectancy. Translational Research, 2011, 158, 307-314.	5.0	13
92	Ranolazine Reduces Ventricular Tachycardia Burden and ICD Shocks in Patients with Drugâ€Refractory ICD Shocks. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1600-1606.	1.2	81
93	A Strategy of Rapid Cardioversion Minimizes the Significance of Early Recurrent Atrial Tachyarrhythmias After Ablation for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2011, 22, 761-766.	1.7	23
94	Patients Treated with Catheter Ablation for Atrial Fibrillation Have Longâ€Term Rates of Death, Stroke, and Dementia Similar to Patients Without Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2011, 22, 839-845.	1.7	349
95	Genome-Wide Significance and Replication of the Chromosome 12p11.22 Locus Near the <i>PTHLH</i> Gene for Peripartum Cardiomyopathy. Circulation: Cardiovascular Genetics, 2011, 4, 359-366.	5.1	69
96	Relation of Elevated Plasma Renin Activity at Baseline to Cardiac Events in Patients With Angiographically Proven Coronary Artery Disease. American Journal of Cardiology, 2010, 106, 764-769.	1.6	46
97	Relation of Vitamin D Deficiency to Cardiovascular Risk Factors, Disease Status, and Incident Events in a General Healthcare Population. American Journal of Cardiology, 2010, 106, 963-968.	1.6	571
98	Long-Term Clinical Efficacy and Risk of Catheter Ablation for Atrial Fibrillation in Octogenarians. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 146-152.	1.2	130
99	The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. European Journal of Heart Failure, 2010, 12, 1203-1213.	7.1	60
100	To the Editor—Response. Heart Rhythm, 2010, 7, e1-e2.	0.7	0
101	Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm, 2010, 7, 433-437.	0.7	331
102	Antilipidemic adherence post-coronary artery disease diagnosis among those with and without an ICD-9 diagnosis of depression. Journal of Psychosomatic Research, 2010, 69, 169-174.	2.6	35
103	Association of vitamin D levels with incident depression among a general cardiovascular population. American Heart Journal, 2010, 159, 1037-1043.	2.7	127
104	Lack of Association of Tegaserod With Adverse Cardiovascular Outcomes in a Matched Case-Control Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2009, 14, 170-175.	2.0	37
105	Effect of work-hour restriction on operative experience in cardiothoracic surgical residency training. Journal of Thoracic and Cardiovascular Surgery, 2009, 137, 710-713.	0.8	90
106	Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation. American Journal of Cardiology, 2009, 103, 824-828.	1.6	70
107	Fasting and Other Health Influences. American Journal of Cardiology, 2009, 103, 1042.	1.6	1
108	Warfarin Is Not Needed in Lowâ€Risk Patients Following Atrial Fibrillation Ablation Procedures. Journal of Cardiovascular Electrophysiology, 2009, 20, 988-993.	1.7	71

#	Article	IF	CITATIONS
109	Superior predictive ability for death of a basic metabolic profile risk score. American Heart Journal, 2009, 157, 946-954.	2.7	9
110	Prognostic value of B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure. American Heart Journal, 2009, 158, 777-783.	2.7	9
111	Exceptional Mortality Prediction by Risk Scores from Common Laboratory Tests. American Journal of Medicine, 2009, 122, 550-558.	1.5	97
112	Depression After Coronary Artery Disease Is Associated With Heart Failure. Journal of the American College of Cardiology, 2009, 53, 1440-1447.	2.8	63
113	Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing. Journal of Thrombosis and Thrombolysis, 2008, 26, 1-7.	2.1	10
114	Comparison of Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Diabetic Patients With Mixed Dyslipidemia (from the) Tj ETQq0 486-489.	0 0 rgBT / 1.6	Oyerlock 10
115	Usefulness of Routine Periodic Fasting to Lower Risk of Coronary Artery Disease in Patients Undergoing Coronary Angiography. American Journal of Cardiology, 2008, 102, 814-819.e1.	1.6	82
116	Relation of Heart Failure Hospitalization to Exposure to Fine Particulate Air Pollution. American Journal of Cardiology, 2008, 102, 1230-1234.	1.6	121
117	Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. American Heart Journal, 2008, 156, 1155-1162.e2.	2.7	67
118	Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation. Circulation, 2007, 116, 2563-2570.	1.6	660
119	Homocysteine Levels Are Associated with Increased Risk of Congestive Heart Failure in Patients with and without Coronary Artery Disease. Cardiology, 2007, 107, 178-184.	1.4	14
120	Surgical Revascularization Is Associated With Improved Long-Term Outcomes Compared With Percutaneous Stenting in Most Subgroups of Patients With Multivessel Coronary Artery Disease. Circulation, 2007, 116, I226-31.	1.6	46
121	Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: Markers for diabetes and cardiovascular risk?. American Heart Journal, 2007, 153, 67-73.	2.7	36
122	Usefulness of a Complete Blood Count-Derived Risk Score to Predict Incident Mortality in Patients With Suspected Cardiovascular Disease. American Journal of Cardiology, 2007, 99, 169-174.	1.6	101
123	Validation of the Seattle Heart Failure Model in a Community-Based Heart Failure Population and Enhancement by Adding B-Type Natriuretic Peptide. American Journal of Cardiology, 2007, 100, 697-700.	1.6	84
124	The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia. Journal of the American College of Cardiology, 2006, 48, 396-401.	2.8	136
125	Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. American Heart Journal, 2006, 152, 997-1003.	2.7	49
126	Relation of Serum Total Cholesterol, C-Reactive Protein Levels, and Statin Therapy to Survival in Heart Failure. American Journal of Cardiology, 2006, 98, 653-658.	1.6	28

#	Article	IF	CITATIONS
127	lschemic Heart Disease Events Triggered by Short-Term Exposure to Fine Particulate Air Pollution. Circulation, 2006, 114, 2443-2448.	1.6	507